文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Role of Probiotics in Gut Microbiome and Metabolome in Non-Alcoholic Fatty Liver Disease Mouse Model: A Comparative Study.

作者信息

Wu Tian, Zeng Zheng, Yu Yanyan

机构信息

Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China.

出版信息

Microorganisms. 2024 May 17;12(5):1020. doi: 10.3390/microorganisms12051020.


DOI:10.3390/microorganisms12051020
PMID:38792849
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11124503/
Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver condition worldwide. Numerous studies conducted recently have demonstrated a connection between the dysbiosis of the development of NAFLD and gut microbiota. Rebuilding a healthy gut ecology has been proposed as a strategy involving the use of probiotics. The purpose of this work is to investigate and compare the function of probiotics () and VSL#3 in NAFLD mice. Rodent NAFLD was modeled using a methionine choline-deficient diet (MCD) with/without oral probiotic delivery. Subsequently, qPCR, histological staining, and liver function tests were conducted. Mass spectrometry-based analysis and 16S rDNA gene sequencing were used to investigate the liver metabolome and gut microbiota. We found that while both and VSL#3 reduced hepatic fat content, outperformed VSL#3. Furthermore, probiotic treatment restored the β diversity of the gut flora and decreased the abundance of pathogenic bacteria such as . These probiotics altered the metabolism in MCD mice, especially the glycerophospholipid metabolism. In conclusion, our findings distinguished the role of and VSL#3 in NAFLD and indicated that oral-gavage probiotics remodel gut microbiota and improve metabolism, raising the possibility of using probiotics in the cure of NAFLD.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11124503/96c6d11b52f3/microorganisms-12-01020-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11124503/8b5b5f46b3a9/microorganisms-12-01020-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11124503/ac20f8e2f00c/microorganisms-12-01020-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11124503/fa6ff69c8380/microorganisms-12-01020-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11124503/0e612632e6d9/microorganisms-12-01020-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11124503/ae53c20a5f72/microorganisms-12-01020-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11124503/dae67fd882d6/microorganisms-12-01020-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11124503/d739e4911c10/microorganisms-12-01020-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11124503/96c6d11b52f3/microorganisms-12-01020-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11124503/8b5b5f46b3a9/microorganisms-12-01020-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11124503/ac20f8e2f00c/microorganisms-12-01020-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11124503/fa6ff69c8380/microorganisms-12-01020-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11124503/0e612632e6d9/microorganisms-12-01020-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11124503/ae53c20a5f72/microorganisms-12-01020-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11124503/dae67fd882d6/microorganisms-12-01020-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11124503/d739e4911c10/microorganisms-12-01020-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e94/11124503/96c6d11b52f3/microorganisms-12-01020-g008.jpg

相似文献

[1]
Role of Probiotics in Gut Microbiome and Metabolome in Non-Alcoholic Fatty Liver Disease Mouse Model: A Comparative Study.

Microorganisms. 2024-5-17

[2]
- A Potential Next-generation Probiotic for Non-alcoholic Fatty Liver Disease.

Curr Pharm Biotechnol. 2024

[3]
Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.

Biomolecules. 2021-12-31

[4]
Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota.

Phytomedicine. 2021-5

[5]
Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice.

Free Radic Biol Med. 2023-2-1

[6]
Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.

World J Gastroenterol. 2018-6-21

[7]
Effects of cholesterol-lowering probiotics on non-alcoholic fatty liver disease in FXR gene knockout mice.

Front Nutr. 2023-7-20

[8]
Identification of a novel probiotic and its protective effects on NAFLD via modulating gut microbial community.

J Sci Food Agric. 2022-8-30

[9]
Xie Zhuo Tiao Zhi formula modulates intestinal microbiota and liver purine metabolism to suppress hepatic steatosis and pyroptosis in NAFLD therapy.

Phytomedicine. 2023-12

[10]
Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway.

J Immunol Res. 2021

引用本文的文献

[1]
Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics.

World J Hepatol. 2025-6-27

[2]
Probiotics and Non-Alcoholic Fatty Liver Disease: Unveiling the Mechanisms of and in Modulating Lipid Metabolism, Inflammation, and Intestinal Barrier Integrity.

Foods. 2024-9-21

[3]
NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options.

Metabolites. 2024-6-28

本文引用的文献

[1]
Long term methionine restriction: Influence on gut microbiome and metabolic characteristics.

Aging Cell. 2024-3

[2]
Paired microbiome and metabolome analyses associate bile acid changes with colorectal cancer progression.

Cell Rep. 2023-8-29

[3]
inhibits nonalcoholic steatohepatitis by orchestrating TLR2-activated γδT17 cell and macrophage polarization.

Gut Microbes. 2023

[4]
Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications.

Front Cell Infect Microbiol. 2022

[5]
NAFLD as the metabolic hallmark of obesity.

Intern Emerg Med. 2023-1

[6]
Imaging and Editing the Phospholipidome.

Acc Chem Res. 2022-11-1

[7]
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms.

Nat Rev Gastroenterol Hepatol. 2022-10

[8]
Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions.

Medicina (Kaunas). 2021-8-14

[9]
Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease.

Metabolism. 2021-10

[10]
Exercise training combined with Bifidobacterium longum OLP-01 treatment regulates insulin resistance and physical performance in db/db mice.

Food Funct. 2021-9-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索